Emyria Ltd · ASX:EMD
Emyria — FY2026 Earnings Presentation
11 slides from Emyria's earnings presentation, Sep 8, 2026
Slide 1: Investor update for the full year ended 30 June 2026
ASX : EMD For personal use only Investor update for the full year ended 30 June 2026 Investor Webinar September 2026
Slide 2: Disclaimer
Disclaimer This presentation has been prepared by Emyria Limited ACN 625 085 734 (Company or Emyria). This presentation is not a financial product or investment advice or recommendation, offer or invitation by any person or to any person to sell or purchase securities in Emyria in any jurisdiction.
Slide 3: Who are we?
Who are we? Emyria is addressing a significant and escalating gap in the mental healthcare market For personal use only Emyria is building a national network of clinics specialising in delivery of Psychedelic Assisted Therapy for PTSD and Treatment Resistant Depression 3 Advanced therapies. Compassi
Slide 4: Worldwide First Mover Advantage
Worldwide First Mover Advantage A Regulated Access Pathway For Psychedelics to Treat our Most Serious and Urgent Mental Health Conditions For personal use only MDMA-assisted therapy This regulation Australia For PTSD change has is the FIRST jurisdiction in created a the world to reschedule Psilocybi
Slide 5: Major Funders are spending Hundreds of Millions each year on mental health
Major Funders are spending Hundreds of Millions each year on mental health For personal use only Private Department of Other Health Insurers Veterans’ Affairs Insurers The Government spends Life insurers … paid out more than $2B $300M/yr on veteran mental health each year. 2 $2.2B in 2024 spent by M
Slide 6: Patient Journey | Treatment Model + Bed Capacity
Patient Journey I Treatment Model + Bed Capacity Medication, ~90 hours of Supervised Intensive Psychotherapy, Follow-Up ACTIVE TREATMENT PROTOCOL BED CAPACITY For personal use only Dosing Dosing Clinic Beds days / week SCREENING Dosing Dosing Day 3 AND Day 1 Day 2 (8 hrs) FOLLOW-UP (8 hrs) Perth (x2
Slide 7: Typical timeline to projected clinic profitability
Typical timeline to projected clinic profitability Current Clinic Status Investment Phase Revenue Generation For personal use only Fit-out & recruitment commences Projected break-even point Months 1-3 Months 4-6 Months 6-9 Months 9-12+ Clinic set-up Open clinic & Dosing day ramp-up Optimise dosing c
Slide 8: Full year ended June in Review: A Year of Demonstrable Growth
Full year ended 30 June in Review: A Year of Demonstrable Growth Yearly Clinics Beds Clinicians Total Authorised Total Patients For personal use only Revenue Operational* Operational* Trained * Prescribers ** Treated ($AUD) (Australia-wide) (Australia-wide) FY25 $1.39M 1 4 ~30 6 24 FY26 $4.05M 5 18
Slide 9: Emyria | Looking Ahead
Emyria | Looking Ahead Delivering on commitments to shareholders For personal use only Core focus areas for financial year 2027: • Increase clinic utilisation of existing clinics in Australia • Continued expansion of Australian clinic network • Continued pursuit of additional reimbursement pathways
Slide 10: Significant momentum in global psychedelic drug treatments
Significant momentum in global psychedelic drug treatments Recent macro catalysts provide significant tailwinds for Emyria For personal use only Emyria is well positioned to leverage this momentum, creating the infrastructure and writing the playbook for psychedelic drug delivery SOURCES 1. https://
Slide 11: Investor Q+A
Investor Q+A For personal use only Greg Hutchinson ghutchinson@emyria.com Mary-Ann Rennie mrennie@emyria.com Visit Our Investor / Investor Hub Media Inquiries investors@emyria.com